Programs

Clinical & Commercial Programs

AIVITA’s lead therapeutic focus is a patient-specific immunotherapy for the treatment of advanced cancers, currently being investigated in glioblastoma and melanoma. We are also developing a personalized vaccine for the prevention of COVID-19.

Cancer

Patient-specific dendritic cell, tumor cell immunotherapy for the treatment of glioblastoma and melanoma.

SARS-CoV-2

Patient-specific dendritic cell vaccine for the prevention of SARS-CoV-2.

Preclinical
Phase 1
Phase 2
Phase 3
Commercialization

Tumor-initiating cell vaccine (Glioblastoma)

Tumor-initiating cell vaccine (Melanoma)

Tumor-initiating cell vaccine + checkpoint inhibitor (Melanoma)

Vaccine Enabling Kit (COVID-19)